Coronary interactions between nifedipine and adenosine in the intact dog heart.
Coronary interactions between nifedipine and adenosine in the intact dog heart.
复制标题
完整狗心脏中硝苯地平和腺苷之间的冠状动脉相互作用。
DOI：
10.1016/0014-2999(82)90343-0
复制
发表时间：
1982
影响因子：
5
通讯作者：
L. Krieger
中科院分区：
文献类型：
--
作者：
G. Merrill;M. Young;S. Dorell;L. Krieger
在开胸、血液灌流的犬心脏上，研究了腺苷和钙通道阻滞剂硝苯地平与冠脉血管的相互作用。腺苷既可以作为冠状动脉内持续输注，也可以在冠状动脉左前降支(LAD)短暂闭塞期间内源性释放。硝苯地平以治疗性浓度单次静脉注射。经股静脉推注。在硝苯地平治疗前，腺苷(1.2Mol/kg/m in)使LAD血流量显著增加(P<；0.05)2-3倍。硝苯地平(6-20μg/kg)剂量依赖性地显著降低上述反应(P<0.05)。平均剂量为11μg/kg硝苯地平后，腺苷(1.2μ/kg/min)不能显著增加左前降支血流量。此外，同样的硝苯地平浓度显著减轻了通过释放30-S阻断的LAD而产生的反应性充血。延长阻断时间(60 S)或增加腺苷输注速度可部分克服硝苯地平介导的衰减。这些结果不能用硝苯地平介导的血流动力学改变来解释，提示腺苷和硝苯地平在血管平滑肌受体上存在药物竞争的可能性。
Coronary vascular interactions between adenosine and the calcium entry blocker, nifedipine were studied in the open-chest, blood-perfused dog heart. Adenosine was administered either as a constant intra-coronary infusion or released endogenously during brief occlusions of the left anterior descending (LAD) coronary artery. Nifedipine was administered in therapeutic concentrations as a single i.v. bolus via the femoral vein. Prior to nifedipine treatment, adenosine (1.2 μmol/kg per min) produced a significant (P < 0.05) 2–3 fold increase in LAD flow. This response was reduced markedly (P < 0.05) in a dose-dependent manner by nifedipine (6–20 μg/kg). Following administration of an average dose of 11 μg/kg nifedipine, adenosine (1.2 μmol/kg per min) failed to elevate LAD flow significantly. Further, reactive hyperemia, produced by releasing a 30-s occlusion of the LAD, was significantly attenuated by these same nifedipine concentrations. The nifedipine-mediated attenuation could be partially overcome by prolonging the period of occlusion (60 s), or by increasing the rate of adenosine infusion. These results could not be accounted for by a nifedipine-mediated alteration of hemodynamics and suggest the possibility of pharmacological competition between adenosine and nifedipine at a vascular smooth muscle receptor.
大鼠睾丸中的腺苷受体：用 3H-环己基腺苷标记。
影响因子：
6.1
作者：
Murphy,KM;Snyder,SH
通讯作者：
Snyder,SH